Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China.
Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China.
Int J Surg. 2017 Aug;44:110-116. doi: 10.1016/j.ijsu.2017.06.050. Epub 2017 Jun 20.
To determine the impact of intraoperative vascular occlusion during liver surgery on postoperative long-term outcomes for hepatocellular carcinoma (HCC) patients using a meta-analysis.
A systematic literature search of PubMed, EMBASE, and Cochrane Central was conducted to discover relevant randomized controlled trials (RCTs) and observational studies. Studies that reported postoperative long-term outcomes; 1-, 3-, and 5-year overall survival (OS); and/or 1-, 3-, and 5-year recurrence-free survival (RFS) for both an observation group (vascular occlusion) and a control group (vascular non-occlusion) were included. Forest plots were performed to calculate the difference between the 2 groups. The Q statistic and the I index statistic were used to assess heterogeneity. Publication bias was evaluated using Egger's test.
Four observational studies containing 2917 patients were included in this meta-analysis. The pooled estimation results indicated that intraoperative vascular occlusion would not shorten the postoperative OS (RR = 1.01; 95%CI: 0.98-1.03; P = 0.763) and would not increase the risk of HCC recurrence (RR = 0.99; 95%CI: 0.97-1.02; P = 0.320) with low heterogeneity (I = 0.0% and 12.7%, respectively). Furthermore, Egger's test did not reveal any publication bias (P = 0.405 and P = 0.269, respectively) in this research.
Intraoperative vascular occlusion during liver surgery is safe for HCC patients. It does not affect the postoperative overall survival or increase the risk of HCC recurrence.
通过荟萃分析,确定肝外科手术中术中血管阻断对肝细胞癌(HCC)患者术后长期结局的影响。
对 PubMed、EMBASE 和 Cochrane Central 进行系统文献检索,以发现相关的随机对照试验(RCT)和观察性研究。纳入报告观察组(血管阻断)和对照组(血管非阻断)术后长期结局、1 年、3 年和 5 年总生存率(OS)和/或 1 年、3 年和 5 年无复发生存率(RFS)的研究。采用森林图计算两组间的差异。采用 Q 统计量和 I 指数统计量评估异质性。采用 Egger 检验评估发表偏倚。
该荟萃分析纳入了 4 项包含 2917 例患者的观察性研究。汇总估计结果表明,术中血管阻断不会缩短术后 OS(RR=1.01;95%CI:0.98-1.03;P=0.763),也不会增加 HCC 复发的风险(RR=0.99;95%CI:0.97-1.02;P=0.320),异质性较低(I=0.0%和 12.7%)。此外,Egger 检验未发现本研究存在任何发表偏倚(P=0.405 和 P=0.269)。
肝外科手术中术中血管阻断对 HCC 患者是安全的。它不会影响术后总体生存率或增加 HCC 复发的风险。